DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Samsung Q2 Profit Seen Soaring as AI Memory Demand Keeps Chip Prices Elevated 
AI Memory Chip Shortage Likely to Persist Despite Korea Investment Boom, Nomura Says 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Foxconn Q2 Revenue Surges Nearly 40% on Strong AI Server Demand 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Boryung Pharmaceutical has added Eli Lily's Gemzar among the anti-cancer drugs that it has rights to distribute in South Korea.
Boryung also has distribution rights to such anti-cancer drugs as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
Boryung CEO Ahn Jae-hyun promised to continue growing its anti-cancer portfolio as the company's focal point.
Gemzar (gemcitabine), a nucleoside metabolic inhibitor, is mainly a pancreatic cancer treatment drug.
Combined with other drugs, Gemzar is used for the treatment of metastatic breast cancer, advanced ovarian cancer, and non-small cell lung cancer.
Gemzar posted 14.2 billion won in revenue in South Korea last year.
